Skip to content
Entourage
Case studyMedTech

Product Portfolio Restructuring and Go-to-Market Strategy for a Medtech Manufacturer

Pharmaceutical and medtech manufacturer in a competitive environment

A pharmaceutical and medtech manufacturer faced intense competitive and cost pressure, without clear product differentiation or a go-to-market strategy, while part of its in-house manufacturing was unprofitable.

The challenge

The situation

A pharmaceutical and medtech manufacturer was exposed to intense competitive and cost pressure, without differentiating product features or a clear go-to-market strategy. In-house manufacturing was partly unprofitable, requiring a comprehensive restructuring of the product portfolio and a robust market-entry strategy.

Our approach

What we delivered

01

Global market analysis and USP development through SWOT analysis and competitive positioning

02

Development of a new go-to-market strategy with portfolio optimisation toward margin-strong products

03

Sales-and-marketing enablement through playbooks and global sales training

The outcome

Results & impact

30% revenue increase

Revenue growth of more than 30% following the strategic restructuring.

1 established market position

Sustainably established position of the manufacturer in the targeted therapeutic field.

3 strategic pillars implemented

Innovation, optimisation and process-improvement pillars successfully implemented.

2 new go-to-market strategies

New strategies developed for market entry and competitive positioning.

In summary

The manufacturer increased revenue by more than 30%, sustainably established its market position, and successfully implemented two new go-to-market strategies.

Sources
  • Entourage project experience (anonymised)

Your project

A comparable project?

Briefly outline your situation. We'll respond with an initial assessment, usually within one business day.

Prefer direct? +49 89 4161170-0
info@theentourage.de

  • Reply usually within one working day
  • 4 offices: DE · CH · IT · US
  • 100% life sciences